Book a demo

Chemical intelligence powered by cypris.ai

Thienpenem

(5R,6S)-3-(2-aminoethylsulfanyl)-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid · also: Tienamycin, Thienamycin, Epithienamycin, Imipenem Impurity A, Imipenem EP Impurity A

FormulaC11H16N2O4S
Mol. weight272.319
PubChem CID441128
InChIKeyWKDDRNSBRWANNC-ATRFCDNQSA-N
SMILESC[C@H]([C@@H]1[C@H]2CC(=C(N2C1=O)C(=O)O)SCCN)O
4,887Patents
81Research papers
195Patents - last 3 years
0Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#AssigneePatents
1Merck and Co Inc627
2Takeda Pharmaceutical Co Ltd404
3Sankyo Co Ltd148
4Eli Lilly and Co129
5Biora Therapeutics Inc70
6Takasago International Corp64
7Allergan Inc57
8Bristol Myers Co53
9Sumitomo Pharma Co Ltd49
10University of California San Diego UCSD46

Explore the full landscape

This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.

Visit Cypris

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#CodeAreaPatents
1A61PTherapeutic activity (drug indications)2,295
2C07DHeterocyclic compounds2,179
3A61KMedicinal preparations2,000
4Y02PClimate change mitigation: production728
5C07FOrganometallic compounds622
6C12NMicroorganisms, enzymes606
7C07CAcyclic and carbocyclic compounds358
8C07KPeptides345
9Y02AClimate change adaptation308
10C12PFermentation, enzyme processes304

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Most-cited patents

Patents ranked by forward citations reveal the foundational inventions the field continues to build on.

TitleYearAssigneeCited by
Substituted N-methylene derivatives of thienamycin1980Merck and Co Inc88
Crystalline N-formimidoyl thienamycin1981Merck and Co Inc57
Thienamycin renal peptidase inhibitors1992Merck and Co Inc39
Process for the preparation of thienamycin and intermediates1980Merck and Co Inc33
Synthesis of thienamycin via trans-3-carboxymethylene-4-carboxy-5-methyl-Δ2 -isoxazoline1981Merck and Co Inc31

Where research is gaining momentum

Research themes ranked by publication activity show where scientific interest is accelerating around this compound.

#Research topicPapers
1Historical Medical Research and Treatments1
2Infections and bacterial resistance1
3Metalloenzymes and iron-sulfur proteins1

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#AuthorAffiliationPapers
1Gloria BlancoUniversidad de Oviedo5
2Alfredo F. BrañaUniversidad de Oviedo4
3Byron H. ArisonMerck & Co., Inc., Rahway, NJ, USA (United States)4
4Craig A. TownsendJohns Hopkins University4
5Edward InamineMerck & Co., Inc., Rahway, NJ, USA (United States)4
6B. G. CHRISTENSENMerck & Co., Inc., Rahway, NJ, USA (United States)3
7Christopher J. SchofieldUniversity of Oxford3
8Cármen MéndezUniversidad de Oviedo3
9Jerrold M. LieschMerck & Co., Inc., Rahway, NJ, USA (United States)3
10Joanne M. WilliamsonMerck & Co., Inc., Rahway, NJ, USA (United States)3

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the molecular formula and weight of Thienpenem?

Thienpenem has the molecular formula C11H16N2O4S and a molecular weight of 272.319 g/mol.

Which organizations hold the most patents related to Thienpenem?

Merck and Co Inc leads with 627 patents, followed by Takeda Pharmaceutical Co Ltd with 404 patents, and Sankyo Co Ltd with 148 patents related to this compound.

What are the primary research topics associated with Thienpenem literature?

Thienpenem research is primarily covered under two key topics: Antibiotic Resistance in Bacteria, including studies on metabolism by renal dipeptidase and its role as a carbapenem antibiotic, and Microbial Natural Products and Biosynthesis, examining its production and biosynthetic pathways.

Who are the most prolific authors publishing on Thienpenem?

Gloria Blanco from Universidad de Oviedo has published 5 papers on the compound. Alfredo F. Braña from Universidad de Oviedo, Byron H. Arison from Merck & Co., Inc., Craig A. Townsend from Johns Hopkins University, and Edward Inamine from Merck & Co., Inc. have each published 4 papers.

What are the most relevant CPC patent classifications for Thienpenem-related patents?

The most heavily patented classification areas are A61P (pharmaceutical and cosmetic preparations, 2295 patents), C07D (heterocyclic compounds, 2179 patents), and A61K (preparations for medical purposes, 2000 patents).

Turn any compound into a complete chemical intelligence landscape

Go beyond static compound data. Cypris resolves identities, patents, papers, and commercial signals into one AI-powered view - so your team can move from a single chemical question to a complete R&D, IP, and market landscape.

Schedule a free trial